Fulcrum Therapeutics, Inc. Gains 38.52%

Fulcrum Therapeutics, Inc. (FULC:NASDAQ) shot up at $5.43, representing a gain of 38.5%. On Tue, Aug 22, 2023, FULC:NASDAQ touched a New 2-Week High of $5.43. The stock got featured on our News Catalysts scanner on Tue, Aug 22, 2023 at 12:14 PM in the 'BIOTECH' category. From Tue, Aug 08, 2023, the stock recorded 50.00% Up Days and 45.45% Green Days

About Fulcrum Therapeutics, Inc. (FULC:NASDAQ)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine which employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle wasting disorder that leads to physical impairments and disability.